Efficacy of Angong Niuhuang Pill for the intravascular treatment of acute large artery occlusio

Early Phase 1

Completed

• Conditions: Cerebrovascular disease

• Registration Number: ITMCTR2024000033
• Lead Sponsor: Affiliated Hangzhou First People's Hospital, Xihu University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Being 18 years of age or older; 2.Having experienced an acute ischemic stroke; 3.Being within 24 hours of stroke onset or last-seen well; 4.Having a National Institutes of Health Stroke Scale (NIHSS) score of at least 6 before entering the trial; 5.Undergoing multimodal imaging assessment where CT artery (CTA) confirmed that the stroke was caused by occlusion of a large vessel in the anterior circulation; 6.The patients or their legal representatives providing signed informed consent.

Exclusion Criteria

1.NCCT suggests intracranial hemorrhage;
2.Active bleeding or a significant bleeding tendency;
3.Patients with renal failure, serum creatinine =264umol/L;
4.pre-existing mRS=2;
5.previous allergy to contrast media; Allergic to known ingredients of Angong Niuhuang pills;
6.Multiple organ failure, can not tolerate surgery
7.The expected survival time of other diseases (such as malignant tumors) is less than 3 months

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
modified Rankin Scale;

Secondary Outcome Measures

Name	Time	Method
Great functional outcomes;Recovery of neurological impairment;Early neurological improvement rate;